Crit Care:液体复苏输液速率对脓毒症性休克患者预后的影响

2020-04-08 MedSci原创 MedSci原创

在脓毒症性休克患者中,与输液速度较慢相比,液体复苏速率为0.25-0.50 ml/kg/min(即,在最初的2h内完成30 ml/kg的静脉液体复苏)可能与早期休克逆转和降低28天死亡率相关。

液体复苏已成为早期脓毒性休克治疗的基石,但最佳液体流速仍未得到很好的研究。近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,该研究旨在评估液体复苏率与脓毒性休克恢复之间的关系。

研究人员回顾性地分析了2006年1月1日至2018年5月31日期间入住梅奥诊所医疗重症监护室(MICU)的成年(≥18岁)脓毒症性休克(根据败血症III来定义)患者。通过输注30μml/kg输液量所需的时间来定义输液复苏时间。根据平均输液速度将队列分为四组(第1组≥0.5,第2组0.25-0.49,第3组0.17-0.24,第4组<0.17ml/kg/min)。该研究的主要结局是逆转休克的时间。研究人员进行了多变量回归分析以说明潜在的混杂因素。

该研究共有1052名患者符合入选标准,并纳入分析。各组间的休克恢复时间显著不同(P<0.001)。与第4组相比,第1组接受更快的液体复苏患者休克逆转的时间较短(HR=0.78;95%CI为0.66-0.91;P=0.01),休克逆转的时间中位数分别为1.7(1.5-2.0)天和2.8(2.6-3.3)天。研究人员使用0.25ml/kg/min作为临界值,较高的输液速度与更短的休克逆转时间(HR=1.22;95%CI为1.06-1.41; P=0.004)和28天死亡几率降低(HR=0.71;95%CI为0.60-0.85;P<0.001)相关。

由此可见,在脓毒症性休克患者中,与输液速度较慢相比,液体复苏速率为0.25-0.50 ml/kg/min(即,在最初的2h内完成30 ml/kg的静脉液体复苏)可能与早期休克逆转和降低28天死亡率相关。

原始出处:

Bo Hu.et al.Effect of initial infusion rates of fluid resuscitation on outcomes in patients with septic shock: a historical cohort study.Critical Care.2020.https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-2819-5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1810511, encodeId=6ea11810511ac, content=<a href='/topic/show?id=8af78519e2d' target=_blank style='color:#2F92EE;'>#脓毒症性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85197, encryptionId=8af78519e2d, topicName=脓毒症性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Mar 04 21:24:43 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692121, encodeId=666c169212156, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 31 22:24:43 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992976, encodeId=8d7819929e627, content=<a href='/topic/show?id=e05e93816f0' target=_blank style='color:#2F92EE;'>#输液速率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93816, encryptionId=e05e93816f0, topicName=输液速率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Wed Aug 19 15:24:43 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305510, encodeId=2059130551087, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556963, encodeId=94ca1556963e7, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1810511, encodeId=6ea11810511ac, content=<a href='/topic/show?id=8af78519e2d' target=_blank style='color:#2F92EE;'>#脓毒症性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85197, encryptionId=8af78519e2d, topicName=脓毒症性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Mar 04 21:24:43 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692121, encodeId=666c169212156, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 31 22:24:43 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992976, encodeId=8d7819929e627, content=<a href='/topic/show?id=e05e93816f0' target=_blank style='color:#2F92EE;'>#输液速率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93816, encryptionId=e05e93816f0, topicName=输液速率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Wed Aug 19 15:24:43 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305510, encodeId=2059130551087, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556963, encodeId=94ca1556963e7, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1810511, encodeId=6ea11810511ac, content=<a href='/topic/show?id=8af78519e2d' target=_blank style='color:#2F92EE;'>#脓毒症性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85197, encryptionId=8af78519e2d, topicName=脓毒症性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Mar 04 21:24:43 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692121, encodeId=666c169212156, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 31 22:24:43 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992976, encodeId=8d7819929e627, content=<a href='/topic/show?id=e05e93816f0' target=_blank style='color:#2F92EE;'>#输液速率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93816, encryptionId=e05e93816f0, topicName=输液速率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Wed Aug 19 15:24:43 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305510, encodeId=2059130551087, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556963, encodeId=94ca1556963e7, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1810511, encodeId=6ea11810511ac, content=<a href='/topic/show?id=8af78519e2d' target=_blank style='color:#2F92EE;'>#脓毒症性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85197, encryptionId=8af78519e2d, topicName=脓毒症性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Mar 04 21:24:43 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692121, encodeId=666c169212156, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 31 22:24:43 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992976, encodeId=8d7819929e627, content=<a href='/topic/show?id=e05e93816f0' target=_blank style='color:#2F92EE;'>#输液速率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93816, encryptionId=e05e93816f0, topicName=输液速率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Wed Aug 19 15:24:43 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305510, encodeId=2059130551087, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556963, encodeId=94ca1556963e7, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
    2020-04-10 lizhou0204
  5. [GetPortalCommentsPageByObjectIdResponse(id=1810511, encodeId=6ea11810511ac, content=<a href='/topic/show?id=8af78519e2d' target=_blank style='color:#2F92EE;'>#脓毒症性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85197, encryptionId=8af78519e2d, topicName=脓毒症性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Mar 04 21:24:43 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692121, encodeId=666c169212156, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 31 22:24:43 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992976, encodeId=8d7819929e627, content=<a href='/topic/show?id=e05e93816f0' target=_blank style='color:#2F92EE;'>#输液速率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93816, encryptionId=e05e93816f0, topicName=输液速率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Wed Aug 19 15:24:43 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305510, encodeId=2059130551087, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556963, encodeId=94ca1556963e7, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Fri Apr 10 11:24:43 CST 2020, time=2020-04-10, status=1, ipAttribution=)]

相关资讯

Heart:经导管二尖瓣修复的左心房压力正常患者特征和预后

TMVR时LAP正常与CLD发病率升高相关,而CLD可独立预测1年死亡率升高。

Sci Rep:手术切除的食管鳞状细胞癌

对于可手术切除的eSCC患者,在PET/CT时测量原发肿瘤的SUVmax可以帮助预测患者的生存率。

J INTERN MED:早期抗病毒治疗有助于缓解新型冠状病毒病感染者的严重程度并改善预后

老年人和有基础疾病的患者更有可能经历严重的COVID‐19。建议及时抗病毒治疗,以延缓病情进展,改善患者预后。

Heart:平均像素强度法预测继发性二尖瓣返流的预后

使用API法进行SMR分级是临床预后的独立预测指标。

Heart:基于深度学习图像分析的法洛四联症预后预测

这项研究提供了关于使用外部影像数据集训练的机器学习算法效用的数据,其可以自动估计ToF患者的预后。

Heart:严重主动脉瓣狭窄患者主动脉瓣置换后的左心室充盈压和生存率

接受AVR的AS患者术前左心室充盈压升高是常见现象,无论其症状如何,均具有重要的预后意义。